Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial evaluates the side effects of uproleselan, azacitidine, and venetoclax in
treating older or unfit patients with treatment naive acute myeloid leukemia. Uproleselan may
help block the formation of growths that may become cancer. Chemotherapy drugs, such as
azacitidine, work in different ways to stop the growth of cancer cells, either by killing the
cells, by stopping them from dividing, or by stopping them from spreading. Venetoclax may
stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Giving uproleselan with azacitidine and venetoclax may help kill more cancer cells.
Phase:
Phase 1
Details
Lead Sponsor:
Brian Jonas
Collaborators:
GlycoMimetics Incorporated National Cancer Institute (NCI)